Solventum

SOLV

Market cap $12.4B

Investors with an interest in Medical Services stocks have likely encountered both Solventum (SOLV) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?

Investors interested in stocks from the Medical Services sector have probably already heard of Solventum (SOLV) and Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?

Here is how Solventum (SOLV) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.

Solventum beats on Q2 earnings, raises guidance, and powers ahead with transformation despite looming tariff headwinds.

FUTU, SITE, CSW, ATRO and SOLV have been added to the Zacks Rank #1 (Strong Buy) List on September 16, 2025.

Solventum Corporation (NYSE:SOLV ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:45 AM EDT Company Participants Wayde McMillan - Chief Financial Officer Garri Garrison - President of Health Information Systems Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Presentation Patrick Wood MD of Equity Research Thanks. Welcome, everybody.

ST. PAUL, Minn. , Sept. 8, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) today announced the pricing terms of its previously announced offers (each, a "Tender Offer" and, collectively, the "Tender Offers") to purchase for an aggregate purchase price of up to $2.0 billion in cash (the "Aggregate Cap") specified series of its outstanding notes (collectively, the "Notes").

ST. PAUL, Minn. , Sept. 8, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) today announced the early tender results of its previously announced offers (each, a "Tender Offer" and, collectively, the "Tender Offers") to purchase its outstanding notes of the series listed in the table below (collectively, the "Notes") for an aggregate purchase price of up to an amended $2.0 billion in cash (the "Aggregate Cap").

Solventum Corporation (NYSE:SOLV ) 2025 Wells Fargo Healthcare Conference September 5, 2025 10:15 AM EDT Company Participants Bryan Hanson - CEO & Director Wayde McMillan - Chief Financial Officer Conference Call Participants Vikramjeet Chopra - Wells Fargo Securities, LLC, Research Division Presentation Vikramjeet Chopra Associate Equity Analyst Okay. Good morning, everyone.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced the completion of its acquisition of the Purification & Filtration business of Solventum (NYSE: SOLV) for approximately $4.0 billion in cash. With the transaction complete, the business, which is now Thermo Fisher's Filtration and Separation business, is part of the Life Sciences Solutions segment. The transaction includes Solventum's Purificatio.